Press Release
For Immediate Release
Date: March 2, 2026
Dr Suman Sahoo Reports Breakthrough Results in POTOMAC Phase III Trial; Launches Bladder Cancer Awareness Webinar
Bhubaneswar, March 2, 2026 — In a significant advancement for uro-oncology, Dr Suman Sahoo has demonstrated statistically significant and clinically meaningful improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) in the landmark POTOMAC Phase III clinical trial. The findings mark a major step forward in improving long-term outcomes for bladder cancer patients.
High-risk non-muscle-invasive bladder cancer has historically posed challenges due to frequent recurrence and progression despite standard therapies. The POTOMAC Phase III trial evaluated advanced therapeutic strategies aimed at reducing recurrence rates and enhancing disease-free survival. The results presented by Dr Sahoo indicate a measurable improvement in patient outcomes, offering renewed hope for individuals battling this aggressive condition.
Recognized as the best uro oncologist in Bhubaneswar, Dr Sahoo emphasized that early diagnosis, risk stratification, and evidence-based treatment protocols are critical to achieving optimal results. “The improvement in disease-free survival demonstrated in the POTOMAC trial reflects the importance of precision-driven treatment approaches in uro-oncology. Our goal is to reduce recurrence and improve quality of life for patients,” he stated.
As part of his commitment to community education and patient empowerment, Dr Sahoo also announced the launch of a dedicated bladder cancer awareness webinar scheduled for March 2, 2026. The online program aims to educate patients, caregivers, and healthcare professionals about:
Early signs and symptoms of bladder cancer


Risk factors and prevention strategies


Advances in minimally invasive treatments


Importance of regular follow-up for high-risk patients


Insights from the POTOMAC Phase III trial


The awareness initiative seeks to bridge the knowledge gap surrounding bladder cancer, particularly among high-risk individuals. With bladder cancer ranking among the most recurrent urological malignancies, timely intervention can significantly impact survival outcomes.
Widely regarded as the Best Urological Cancer Doctor in Bhubaneswar, Dr Sahoo has consistently advocated for integrating research findings into clinical practice. His leadership in presenting the POTOMAC trial data highlights Bhubaneswar’s growing role in advanced cancer care and clinical innovation.
The webinar will provide attendees with evidence-based guidance, interactive Q&A sessions, and practical advice on navigating diagnosis and treatment pathways. Participants will gain clarity on how modern therapies are transforming the management of high-risk NMIBC.
Healthcare professionals attending the session will also receive insights into trial methodology, statistical endpoints, and clinical implications of the POTOMAC findings. The program underscores the importance of collaborative, research-driven oncology care.
Dr Sahoo reiterated that patient awareness remains a cornerstone of improved survival. “Breakthrough research must translate into accessible care and informed decision-making. Through this webinar, we aim to empower patients with knowledge and confidence,” he added.
With demonstrated expertise and dedication to advancing uro-oncology, Dr Suman Sahoo continues to set new benchmarks in cancer treatment. His contributions through the POTOMAC Phase III trial reinforce his reputation as the best uro oncologist in Bhubaneswar and a leading authority in bladder cancer management.
For registration details and webinar access information, interested participants are encouraged to follow upcoming announcements across leading news channels and digital platforms.
Media Contact:
Office of Dr Suman Sahoo
Bhubaneswar
Email: [email protected]
Visit: https://drsumansahoourologist.in/